ProCE Banner Activity

IMpower010: Updated Data of Phase III Trial of Adjuvant Atezolizumab vs BSC in Resected Stage IB-IIIA NSCLC After Adjuvant Chemotherapy

Slideset Download
Interim analysis of OS suggests a trend toward benefit with adjuvant atezolizumab following complete resection and adjuvant chemotherapy in patients with stage II-IIIA NSCLC with PD-L1 TC ≥1% vs BSC.

Released: August 16, 2022

Expiration: August 15, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc